Glen Reid

List of Publications by Citations

94 papers	6,151 citations	38 h-index	78 g-index
103 ext. papers	6,789 ext. citations	5.3 avg, IF	5.55 L-index

#	Paper	IF	Citations
94	The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 9244-9	11.5	425
93	Haemolysis during sample preparation alters microRNA content of plasma. *PLoS ONE*, **2011**, 6, e24145	3.7	380
92	Circulating microRNAs: Association with disease and potential use as biomarkers. *Critical Reviews in Oncology/Hematology*, **2011**, 80, 193-208	7	372
91	Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. *Lancet Oncology, The*, **2017**, 18, 1386-1396	21.7	330
90	Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. *Molecular Cancer Therapeutics*, **2002**, 1, 417-25	6.1	324
89	Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. *Molecular Pharmacology*, **2003**, 63, 1094-103	4.3	315
88	Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). *Biochemical Journal*, **2003**, 371, 361-7	3.8	277
87	The Impact of Hemolysis on Cell-Free microRNA Biomarkers. *Frontiers in Genetics*, **2013**, 4, 94	4.5	211
86	Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. *Journal of Biological Chemistry*, **2003**, 278, 17664-71	5.4	210
85	Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). *Journal of Biological Chemistry*, **2001**, 276, 46400-7	5.4	202
84	Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. *Journal of Biological Chemistry*, **2004**, 279, 22250-7	5.4	191
83	Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma. *Annals of Oncology*, **2013**, 24, 3128-35	10.3	167
82	Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). *Journal of Biological Chemistry*, **2003**, 278, 23538-44	5.4	167
81	Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. *Molecular Pharmacology*, **2002**, 62, 1321-31	4.3	164
80	Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer. *Epigenomics*, **2016**, 8, 1079-85	4.4	124
79	Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer. *Biophysical Reviews*, **2018**, 10, 69-86	3.7	107
78	The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. *Cancer Research*, **2005**, 65, 4425-30	10.1	102

77	Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma. *Journal of Thoracic Oncology*, **2017**, 12, 1421-1433	8.9	97
76	Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. *Journal of Thoracic Oncology*, **2012**, 7, 1184-91	8.9	95
75	The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction. *FASEB Journal*, **2007**, 21, 3592-605	0.9	84
74	YB-1, the E2F pathway, and regulation of tumor cell growth. *Journal of the National Cancer Institute*, **2012**, 104, 133-46	9.7	79
73	Cloning of a human renal p-aminohippurate transporter, hROAT1. *Kidney and Blood Pressure Research*, **1998**, 21, 233-7	3.1	78
72	Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. *Journal of Clinical Pathology*, **2013**, 66, 847-53	3.9	74
71	Protein kinase C activation downregulates human organic anion transporter 1-mediated transport through carrier internalization. *Journal of the American Society of Nephrology: JASN*, **2003**, 14, 1959-68	12.7	74
70	Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. *Journal of Thoracic Oncology*, **2011**, 6, 1923-9	8.9	71
69	miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma. *Oncotarget*, **2015**, 6, 23480-95	3.3	68
68	MicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma. *Oncotarget*, **2015**, 6, 36675-88	3.3	62
67	A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural Mesothelioma. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 191, 1467-9	10.2	54
66	MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. *Molecular Oncology*, **2015**, 9, 715-26	7.9	54
65	Cell-free microRNAs: potential biomarkers in need of standardized reporting. *Frontiers in Genetics*, **2013**, 4, 56	4.5	53
64	Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. *Advanced Drug Delivery Reviews*, **2002**, 54, 1333-42	18.5	51
63	Genomic structure and in vivo expression of the human organic anion transporter 1 (hOAT1) gene. *Biochemical and Biophysical Research Communications*, **2000**, 275, 623-30	3.4	50
62	The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. *Antiviral Research*, **2004**, 62, 1-7	10.8	49
61	Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis. *British Journal of Cancer*, **2015**, 113, 963-9	8.7	48
60	Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. *Cancer Chemotherapy and Pharmacology*, **2011**, 68, 603-10	3.5	41

59	Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma. *Molecular Cancer Research*, **2015**, 13, 1106-18	6.6	38
58	Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. *Journal of Clinical Pathology*, **2013**, 66, 854-61	3.9	38
57	Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer. *Drug Metabolism Reviews*, **2010**, 42, 590-611	7	38
56	An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. *British Journal of Cancer*, **2014**, 110, 510-9	8.7	37
55	KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma. *Molecular Cancer*, **2016**, 15, 44	42.1	36
54	An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. *Journal of Clinical Medicine*, **2018**, 7,	5.1	36
53	MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets. *Journal of Thoracic Disease*, **2015**, 7, 1031-40	2.6	34
52	A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis. *Npj Systems Biology and Applications*, **2018**, 4, 20	5	33
51	Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma. *Journal of Thoracic Oncology*, **2018**, 13, 258-272	8.9	29
50	Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM). *PLoS ONE*, **2013**, 8, e70940	3.7	28
49	Exploring Mechanisms of MicroRNA Downregulation in Cancer. *MicroRNA (Shariqah, United Arab Emirates)*, **2017**, 6, 2-16	2.9	28
48	ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma. *Journal of Thoracic Oncology*, **2013**, 8, 1317-28	8.9	25
47	Malignant mesothelioma. *Internal Medicine Journal*, **2010**, 40, 742-50	1.6	25
46	Mutational analysis of hedgehog signaling pathway genes in human malignant mesothelioma. *PLoS ONE*, **2013**, 8, e66685	3.7	25
45	Validation of tissue microarray technology in malignant pleural mesothelioma. *Pathology*, **2011**, 43, 128-32	1.6	24
44	Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins □3 and □5. *PLoS ONE*, **2014**, 9, e90374	3.7	23
43	The □133p53□isoform promotes an immunosuppressive environment leading to aggressive prostate cancer. *Cell Death and Disease*, **2019**, 10, 631	9.8	22
42	Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase. *Journal of Rnai and Gene Silencing*, **2009**, 5, 321-30		22

41	Inflammation in malignant mesothelioma - friend or foe?. *Annals of Cardiothoracic Surgery*, **2012**, 1, 516-22	4.7	21
40	A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5SRACE and a molecular beacon probe. *Nucleic Acids Research*, **2010**, 38, e19	20.1	19
39	FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal. *Carcinogenesis*, **2018**, 39, 534-545	4.6	18
38	A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma. *Molecular Oncology*, **2018**, 12, 58-73	7.9	18
37	Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future. *Frontiers in Oncology*, **2020**, 10, 105	5.3	17
36	Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study. *European Journal of Cancer*, **2016**, 63, 64-73	7.5	17
35	Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma. *Frontiers in Cell and Developmental Biology*, **2019**, 7, 221	5.7	17
34	Blockade of aquaporin 1 inhibits proliferation, motility, and metastatic potential of mesothelioma in vitro but not in an in vivo model. *Disease Markers*, **2015**, 2015, 286719	3.2	16
33	Exploiting microRNAs As Cancer Therapeutics. *Targeted Oncology*, **2017**, 12, 163-178	5	15
32	High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. *Lung Cancer*, **2019**, 130, 35-41	5.9	15
31	A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma. *British Journal of Cancer*, **2016**, 114, 524-31	8.7	15
30	Molecular biomarkers in malignant mesothelioma: state of the art. *Pathology*, **2011**, 43, 201-12	1.6	14
29	Abstract 3976: Targeted delivery of a synthetic microRNA-based mimic as an approach to cancer therapy **2015**,		14
28	Asbestos-related cancers: the SHidden KillerSremains a global threat. *Expert Review of Anticancer Therapy*, **2020**, 20, 271-278	3.5	12
27	Tumour Suppressor Genes Are Potential Plasma-Based Epigenetic Biomarkers for Malignant Pleural Mesothelioma. *Disease Markers*, **2017**, 2017, 2536187	3.2	12
26	Extracellular vesicles as biomarkers in malignant pleural mesothelioma: A review. *Critical Reviews in Oncology/Hematology*, **2020**, 150, 102949	7	11
25	The importance of RT-qPCR primer design for the detection of siRNA-mediated mRNA silencing. *BMC Research Notes*, **2011**, 4, 148	2.3	10
24	The potency of siRNA-mediated growth inhibition following silencing of essential genes is dependent on siRNA design and varies with target sequence. *Oligonucleotides*, **2009**, 19, 317-28		9

23	Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma. *Oncotarget*, **2019**, 10, 4125-4138	3.3	8
22	THE MULTIDRUG RESISTANCE PROTEINS 3 **2003**, 445-458		6
21	Response to "An innovative mesothelioma treatment based on mir-16 mimic loaded EGFR targeted minicells (TargomiRs)". *Translational Lung Cancer Research*, **2018**, 7, S60-S61	4.4	6
20	Phenotypic screen for oxygen consumption rate identifies an anti-cancer naphthoquinone that induces mitochondrial oxidative stress. *Redox Biology*, **2020**, 28, 101374	11.3	6
19	BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state. *PLoS ONE*, **2018**, 13, e0203003	3.7	6
18	The analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection. *BMC Research Notes*, **2017**, 10, 600	2.3	5
17	Posttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma. *Frontiers in Genetics*, **2017**, 8, 70	4.5	5
16	When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. *Frontiers in Endocrinology*, **2019**, 10, 89	5.7	4
15	MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients. *Genomics Data*, **2016**, 9, 44-9		4
14	P1.05-021 circRNAs: Potential Novel Biomarkers for the Early Detection of Lung Cancer. *Journal of Thoracic Oncology*, **2017**, 12, S626-S627	8.9	3
13	Zeolites ameliorate asbestos toxicity in a transgenic model of malignant mesothelioma. *FASEB BioAdvances*, **2019**, 1, 550-560	2.8	3
12	Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?. *Annals of Cardiothoracic Surgery*, **2012**, 1, 481-6	4.7	3
11	YB-1 Knockdown Inhibits the Proliferation of Mesothelioma Cells through Multiple Mechanisms. *Cancers*, **2020**, 12,	6.6	3
10	Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways. **2019**, 2, 1193-1206		2
9	Asbestos and Zeolites: from A to Z via a Common Ion. *Chemical Research in Toxicology*, **2021**, 34, 936-9514		2
8	Differential Expression of Isoforms in Melanoma. *Genes*, **2021**, 12,	4.2	2
7	Covalent binding of molecules to plasma immersion ion implantation-activated microparticles for delivery into cells. *Engineering Reports*, **2020**, 2, e12087	1.2	1
6	Asbestos and the Pathophysiology of Mesothelioma **2019**, 19-33		1

5	Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population. *JTO Clinical and Research Reports*, **2020**, 1, 100075	1.4	1
4	MicroRNAs and Cancer **2015**, 67-90		
3	Welcome message from conference co-convenors. *Asia-Pacific Journal of Clinical Oncology*, **2014**, 10 Suppl 7, 1	1.9	
2	Does miR-1 play a role in malignant pleural mesothelioma development and progression?. *Chest*, **2013**, 144, 1971	5.3	
1	Using a multidisciplinary approach to combat the burden of asbestos-related disease. *Medical Journal of Australia*, **2016**, 204, 52	4	